Aktia höjer sin primeränta till 2,50 procent den 2 oktober 2023
Aktia Bank Abp
Pressmeddelande
18.9.2023 kl. 9.00
Aktia höjer sin primeränta till 2,50 procent den 2 oktober 2023
Aktia Bank höjer sin primeränta från 2,00 procent till 2,50 procent. Räntehöjningen träder i kraft den 2 oktober 2023. Förändringen beror på att marknadsräntorna har stigit.
Aktia Bank Abp
Mera information:
Timo Ruotsalainen, Head of Treasury, tfn 010 247 7211
Distribution:
Nasdaq Helsinki Oy
Massmedier
www.aktia.com
Aktia är en finländsk kapitalförvaltare, bank och livförsäkrare som har skapat välstånd och välfärd generation efter generation redan under 200 års tid. Vi tillhandahåller våra kunder digitala tjänster i ett flertal kanaler och ger personlig service på våra verksamhetsställen i huvudstadsregionen samt i Åbo-, Tammerfors-, Vasa- och Uleåborgsregionerna. Vår prisbelönta kapitalförvaltnings fonder säljs även internationellt. Vi sysselsätter cirka 900 personer på olika håll i Finland. Aktias förvaltade kundmedel (AuM) 30.06.2023 uppgick till 13,8 miljarder euro och balansomslutningen till 12,3 miljarder euro. Aktias aktie noteras på Nasdaq Helsinki Oy (AKTIA). aktia.com
För att se det här innehållet från www.globenewswire.com måste du ge ditt medgivande sidans topp.För att se det här innehållet från ml-eu.globenewswire.com måste du ge ditt medgivande sidans topp.
Om
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Följ GlobeNewswire by notified
Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.
Senaste pressmeddelandena från GlobeNewswire by notified
PHAXIAM Therapeutics and Vetophage Announce Strategic Research Collaboration3.10.2023 22:05:00 CEST | Press release
PHAXIAM Therapeutics and Vetophage Announce Strategic ResearchCollaboration Strategic research partnership between PHAXIAM Therapeutics and Vetophage, a biotechnology company specialized in veterinary phage therapy Combining expertise in the research of new phages and phage endolysins that could be applied to human health Exclusive phage and endolysin licensing options in human health for PHAXIAM Therapeutics Lyon (France) and Cambridge (MA, US), October03, 2023 – 10:05pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM) and Vetophage, a company specialized in phage therapy applied to animal health, announce the signature of a long-term strategic research partnership to combine their expertise in the research of new phages and phage-derived proteins (endolysins) in the fight against antimicrobial resistance. Vetophage is a Lyon-based biotechnology company founded in 2017. It develops new tools to detect pathogenic bacteria and alternative solutions to antibiotics based on phages an
Kvika banki hf.: TM Insurance to be sold or listed3.10.2023 21:05:43 CEST | Press release
Following a strategic review at Kvika banki hf. ("Kvika" or "the bank"), the board of directors of Kvika has decided to initiate a process for the sale or listing of its insurance subsidiary TM tryggingar hf. ("TM"). The decision is in line with the bank's vision, where emphasis is placed on simplifying the group's operations and strengthening Kvika's traditional banking activities, in accordance with the bank's goal to increase competition and simplify its customers' finances. Following the divestment of TM, Kvika's main operations will be focused on commercial- and investment banking, along with asset management. It is expected that Kvika's capital base will grow significantly following the divestment of TM, enabling the bank to pursue internal growth opportunities across Kvika's business segments. Increased capital will, among other things, enable the bank to strengthen its market position, in both retail and corporate lending, and increase the risk diversification of its loan book.
Policane® Natural Sweetener Found to Have Low Glycemic Index3.10.2023 20:06:38 CEST | Press release
OCALA, Fla., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Policane®, a natural sweetener made from sugar cane juice in a patented process, has been found to have a low glycemic index (GI) in a study by IFP Suisse SA. According to the study Policane® has a GI of 51.7+/- 3.66. The study also found that Policane® had a 42% lower GI than white sugar. In its conclusion, the study recommends for Policane® a low glycaemic index product classification under International Standard ISO26642. “We are excited to share the results of this study, providing that Policane® is a low-GI sweetener,” said Jorge Enrique Gonzalez, Manager and CEO at PoliCane Co., LLC. “Policane® retains the best parts of the sugar cane stripped away in refined sugar. Policane® is a natural and sustainable sweetener that the world needs.” Policane® is currently produced under license in Costa Rica and can be used in recipes for all sweetened food and beverages, including baked goods, coffee, tea, colas, sauces, ketchup and desserts. Fo
Nokia Corporation: Repurchase of own shares on 03.10.20233.10.2023 20:00:00 CEST | Press release
Nokia Corporation Stock Exchange Release 3 October 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 03.10.2023 Espoo, Finland – On 3 October 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL344,5423.53CEUX39,5413.54AQEU1,3923.53TQEX14,5253.55Total400,0003.53 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023
Adevinta ASA – Procedures established in response to receipt of non-binding indicative proposal3.10.2023 19:30:00 CEST | Press release
Oslo, 3 October 2023 – Adevinta ASA (“Adevinta” or the “Company”) refers to the stock exchange announcement on 21 September 2023 regarding receipt of a non-binding indicative proposal (the “Proposal”) from a consortium led by Permira and Blackstone, with involvement of the Company’s two main shareholders, regarding a potential offer for all shares of the Company. In response to shareholder enquiries, the Company wants to communicate the procedures it is following in response to the Proposal. Immediately upon receipt of the Proposal, the Company’s board of directors established a special committee comprising the five independent directors on the Company’s board. The special committee is representing the Company in all aspects relating to the Proposal. The directors who are representatives of the three main shareholders of the Company are not involved in the Company’s deliberations and decisions. The independent committee is actively engaging in the Proposal in line with applicable regul